Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1

GlobeNewswire December 12, 2017

Resverlogix Repays $68.8 Million Loan

GlobeNewswire December 6, 2017

Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink

GlobeNewswire December 4, 2017

Resverlogix Announces Participation in Upcoming Conferences

GlobeNewswire November 2, 2017

Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

GlobeNewswire November 1, 2017

Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.

GlobeNewswire October 24, 2017

IIROC Trade Resumption - RVX

Canada NewsWire October 13, 2017

IIROC Trade Resumption - Resverlogix Corp.

Newsfile October 13, 2017

IIROC Trading Halt - RVX

Canada NewsWire October 13, 2017

Resverlogix Announces $87 Million Private Placement with Shenzhen Hepalink

GlobeNewswire October 13, 2017

IIROC Trade Halt - Resverlogix Corp.

Newsfile October 13, 2017

Resverlogix Announces Annual and Special Meeting of Shareholders

GlobeNewswire October 2, 2017

Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

PR Newswire September 13, 2017

Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement

Canada NewsWire September 5, 2017

Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial

Canada NewsWire August 29, 2017

Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction

PR Newswire August 28, 2017

Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017

Canada NewsWire July 25, 2017

IIROC Trade Resumption - RVX

Canada NewsWire July 25, 2017

IIROC Trade Resumption - Resverlogix Corp.

Newsfile July 25, 2017

Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

Canada NewsWire July 25, 2017